Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 5:41 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 81 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Metastatic Hormone Sensitive Prostate Cancer Clear all

Conditions: Metastatic Hormone Refractory Prostate Cancer
Interventions: Cabozantinib, Nivolumab, Abiraterone acetate, Prednisone, Peripheral blood collection; Drug · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Male only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer
Interventions: ASP5541, Prednisone, Prednisolone, abiraterone acetate, Adrenocorticotropic hormone; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 12
States / cities: Huntsville, Alabama • San Diego, California • Tampa, Florida + 9 more

Conditions: Prostatic Neoplasms
Interventions: Niraparib+ Abiraterone acetate fixed dose combination (FDC), Abiraterone acetate (AA), Prednisone, Placebo FDC, Placebo AA; Combination Product · Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 696 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 53
States / cities: Homewood, Alabama • Phoenix, Arizona • Tucson, Arizona + 45 more

Conditions: Metastatic Castration-resistant Prostate Neoplasms, Metastatic Hormone-sensitive Prostate Cancer
Interventions: Pasritamig, Cetrelimab, Cabazitaxel, Docetaxel, Apalutamide, Enzalutamide, Darolutamide, Abiraterone acetate plus prednisone (AAP), Lutetium Lu-177 vipivotide tetraxetan, JNJ-101556143; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 7
States / cities: Sarasota, Florida • Grand Rapids, Michigan • Brooklyn, Mississippi + 4 more

Conditions: Prostate Cancer Metastatic
Interventions: Rucaparib; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 2
States / cities: Baltimore, Maryland • New York, New York

Conditions: PSA Level Greater Than Two, Stage IV Prostate Adenocarcinoma AJCC v7
Interventions: Bicalutamide, Goserelin Acetate, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Leuprolide Acetate; Drug · Radiation · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2027
U.S. locations: 2
States / cities: Duarte, California • South Pasadena, California

Conditions: Castration-Sensitive Prostate Carcinoma, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer
Interventions: Abiraterone Acetate, Antiandrogen Therapy, Docetaxel, Prednisone, Quality-of-Life Assessment, Questionnaire Administration; Drug · Other
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older · Male only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Metastatic Castration Resistant Prostate Cancer
Interventions: Rinzimetostat, Darolutamide, Enzalutamide, Docetaxel; Drug
Lead sponsor: ORIC Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 14
States / cities: Glendale, California • Coral Springs, Florida • Jeffersonville, Indiana + 11 more

Conditions: Metastatic Hormone-Sensitive Prostate Cancer
Interventions: Pembrolizumab, Enzalutamide, Androgen Deprivation Therapy (ADT), Placebo; Biological · Drug · Other
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,251 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 27
States / cities: Anchorage, Alaska • Duarte, California • Los Angeles, California + 22 more

Conditions: Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions: enzalutamide, bicalutamide, orchiectomy, leuprolide acetate, goserelin acetate, laboratory biomarker analysis; Drug · Procedure · Other
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 4
States / cities: Birmingham, Alabama • Detroit, Michigan • Columbus, Ohio

Conditions: Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer
Interventions: PRL-02 injection, prednisone, dexamethasone, enzalutamide; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 24
States / cities: Tucson, Arizona • Anaheim, California • Santa Rosa, California + 20 more

Conditions: Castration-Sensitive Prostate Adenocarcinoma, Metastatic Castration-Sensitive Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: Androgen Receptor Pathway Inhibitor, Transdermal Estrogen, Bone Scan, Computed Tomography, Dual X-ray Absorptiometry, Gonadotropin-releasing Hormone Analog, Magnetic Resonance Imaging, Survey Administration, Biospecimen Collection; Drug · Procedure · Biological + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions: Abiraterone Acetate, Bicalutamide, Degarelix, Goserelin Acetate, Leuprolide Acetate, Prednisone, Questionnaire Administration, Talazoparib; Drug · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Prostatic Neoplasms
Interventions: 177Lu-PSMA-617, 68Ga-PSMA-11, ARDT, ADT; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 1,144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 67
States / cities: Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 49 more

Conditions: Metastatic Castration Sensitive Prostate Cancer (mCSPC), Cancer of the Prostate, Prostate Neoplasms, Prostate Cancer
Interventions: Enzalutamide, Apalutamide; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer Metastatic
Interventions: REGN2810, Degarelix, Leuprolide Acetate, Docetaxel; Drug
Lead sponsor: Mark Stein; Other
Eligibility: 18 Years to 99 Years · Male only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostatic Neoplasms
Interventions: Novel hormonal therapy; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 65 Years and older · Male only
Enrollment: 3,017 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer
Interventions: Standard ADT, Dovitinib; Drug
Lead sponsor: Oscar Goodman, Jr.; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Interventions: relugolix + ARPI., Intermittent- Relugolix or androgen deprivation therapy (ADT) + ARPI, relugolix or androgen deprivation therapy (ADT) + ARPI; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older · Male only
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Metastatic Hormone-Sensitive Prostate Cancer
Interventions: PROSTVAC-V, PROSTVAC-F, Nivolumab, Ipilimumab, Neoantigen DNA vaccine, TriGrid Delivery System, Tumor biopsy, Peripheral blood, Fecal samples, Leukapheresis; Biological · Drug · Device + 1 more
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Male only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: Abiraterone, Biospecimen Collection, Bone Scan, Computed Tomography, Docetaxel, Enzalutamide, FDG-Positron Emission Tomography, Magnetic Resonance Imaging, PSMA PET Scan, Vudalimab; Drug · Procedure
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Prostate Cancer, Castration Sensitive Prostate Cancer, Metastatic Prostate Cancer, Adaptive Radiotherapy
Interventions: Drug: 68-Ga PSMA11, Adaptive stereotactic ablative radiotherapy (SABR), 68Ga-PSMA-11, Adaptive stereotactive ablative radiotherapy (SABR); Drug · Radiation
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Metastatic Castrate-sensitive Prostate Cancer
Interventions: Apalutamide, Androgen-deprivation Therapy (ADT); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 46
States / cities: Homewood, Alabama • Tucson, Arizona • Little Rock, Arkansas + 37 more

Conditions: Prostate Cancer (Adenocarcinoma)
Interventions: Abiraterone, Enzalutamide, Apalutamide, Darolutamide (BAY 1841788), Docetaxel, ADT; Drug
Lead sponsor: Canadian Cancer Trials Group; Network
Eligibility: 18 Years and older · Male only
Enrollment: 830 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 374
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 272 more

Search by objective public record fields.

Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)

A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations

Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer

Docetaxel or Abiraterone Acetate With ADT in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer

A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)

LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer

A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial

Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer

An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

A Study to Learn About Two Medicines (Apalutamide and Enzalutamide) in People With Metastatic Castration-sensitive Prostate Cancer (mCSPC)

REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer

A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

A Study of Dovitinib With Androgen Deprivation Therapy (ADT) in Patients With Metastatic Prostate Cancer Receiving Primary ADT

Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer

Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer

Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer

Response With Interim PSMA PET in Metastatic Castration-sensitive Prostate Cancer for Optimization of Adaptive Metastasis-directed Radiotherapy Delivery

A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response